Effects of sympatholytic therapy on postmenopausal symptoms in hypertensive postmenopausal women

References

• AACE Menopause Guidelines Revision Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause. Endocr Pract 2006;12:315–37
   PubMedGoogle Scholar
• Mohyi D, Tabassi K, Simon J. Differential diagnosis of hot flushes. Maturitas 1997;27:203–14
   PubMed Web of Science ®Google Scholar
• Oldenhave A, Netelenbons C. Pathogenesis of climacteric complaints: ready for change. Lancet 1994;343:649–53
   PubMed Web of Science ®Google Scholar
• Takamatsu K, Ohta H, Makita K, Horiguchi F, Nozawa S. Effects of counseling on climacteric symptoms in Japanese postmenopausal women. J Obstet Gynecol 2001;27:133–40
   Google Scholar
• Staessen JA, Bieniaszewski L, Brosens I, Fagard R. The epidemiology of menopause and its association with cardiovascular disease. In Messerli FH, eds Hypertension in Postmenopausal Women. New York: Marcel Dekker Inc, 1996:43–78
   Google Scholar
• Taler SJ. Hypertension in women. Curr Hypertens Rep 2009;11:23–8
   PubMed Web of Science ®Google Scholar
• Starapoli CA, Flaws JA, Bush TL, Moulton AW. Predictors of menopausal hot flushes. J Womens Health 1998;7:1149–55
   PubMed Web of Science ®Google Scholar
• Gold EB, Sternfeld B, Kelsey JL, et al. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40–55 years of age. Am J Epidemiol 2000;152:463–73
   PubMed Web of Science ®Google Scholar
• Thurston RC, Sowers MR, Sutton-Tyrrell K, et al. Abdominal adiposity and hot flushes among midlife women. Menopause 2008;15:429–34
   PubMed Web of Science ®Google Scholar
• James GD, Sievert LL, Flanagan E. Ambulatory blood pressure and heart rate in relation to hot flash experience among women of menopausal age. Ann Human Biol 2004;31:49–58
   PubMed Web of Science ®Google Scholar
• Gerber LM, Sievert LL, Warren K, Pickering TG, Schwartz JE. Hot flushes are associated with ambulatory blood pressure. Menopause 2007;14:308–15
   PubMed Web of Science ®Google Scholar
• Ikeda H, Inou T, Uemura S, Kaibara R, Tanaka H, Node K. Effects of candesartan for middle-aged and elderly women with hypertension and menopausal-like symptoms. Hypertens Res 2006;29:1007–12
   PubMed Web of Science ®Google Scholar
• Freedman RR. Biochemical, metabolic and vascular mechanisms in menopausal hot flushes. Fertil Steril 1998;70:332–7
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465–77
   PubMed Web of Science ®Google Scholar
• Huang AJ, Sawaya GF, Vittinghoff E, Lin F, Grady D. Hot flushes, coronary heart disease, and hormone therapy in postmenopausal women. Menopause 2009;16:639–43
   PubMed Web of Science ®Google Scholar
• Lee SW, Jo HH, Kim MR, Kwon DJ, You YO, Kim JH. Association between menopausal symptoms and metabolic syndrome in postmenopausal women. Arch Gynecol Obstet 2012;285:541–8
   PubMed Web of Science ®Google Scholar
• Thurston RC, El Khoudary SR, Sutton-Tyrrell K, et al. Vasomotor symptoms and insulin resistance in the Study of Women’s Health Across the Nation. J Clin Endocrinol Metab 2012;97:3487–94
   PubMed Web of Science ®Google Scholar
• Tuomikoski P, Ylikorkala O, Mikkola TS. Menopausal hot flashes and insulin resistance. Menopause 2012;19:1116–20
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al.; Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Hendrix SL, Langer RD, et al.; WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative randomized trial. JAMA 2003;289: 3243–53
   PubMed Web of Science ®Google Scholar
• Manson JE, Hsia J, Johnson KC, et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523–34
   PubMed Web of Science ®Google Scholar
• Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: The Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2663–72
   PubMed Web of Science ®Google Scholar
• Grodstein F, Mason JE, Stampfer MJ, Rexrode K. Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. Arch Intern Med 2008;168:861–6
   PubMed Web of Science ®Google Scholar
• Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573–80.
   PubMed Web of Science ®Google Scholar
• Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in post-menopausal women: systematic review and meta-analysis. BMJ 2008;336:1227–31
   PubMed Web of Science ®Google Scholar
• Taylor HS, Manson JE. Update in hormone therapy use in menopause. J Clin Endocrinol Metab 2011;96:255–64
   PubMed Web of Science ®Google Scholar
• Matsuda M, DeFronzo R. Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabetes Care 1999;22: 1462–79
   PubMed Web of Science ®Google Scholar
• Kaaja R, Kujala S, Manhem K, et al.J. Effects of sympatholytic therapy on insulin sensitivity indices in hypertensive postmenopausal women. Int J Clin Pharm Ther 2007;45:394–401
   PubMed Web of Science ®Google Scholar
• Freedman RR, Krell W. Reduced thermoregulatory null zone in post-menopausal women with hot flushes. Am J Obstet Gynecol 1999;181:66–70
   PubMed Web of Science ®Google Scholar
• North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: position statement of The North American Menopause Society. Menopause 2004;11: 11–33
   PubMed Web of Science ®Google Scholar
• Simpkins JW, Kalra SP. Central site(s) of norepinephrine and LHRH interaction. Fed Proc 1979;38:1107
   Google Scholar
• Laufer LR, Erlik Y, Meldrum DR, Judd HL. Effect of clonidine on hot flushes in postmenopausal women. Obstet Gynecol 1982;60:583–6
   PubMed Web of Science ®Google Scholar
• Schindler AE, Muller D, Keller E, Goser R, Runkel F. Studies with clonidine (Dixarit) in menopausal women. Arch Gynecol 1979; 227:341–7
   PubMedGoogle Scholar
• Tulandi T, Lal S, Kinch RA. Effect of intravenous clonidine on menopausal flushing and luteinising hormone secretion. Br J Obstet Gynaecol 1983;90:854–7
   PubMedGoogle Scholar
• Claydon JR, Bell JW, Pollard P. Menopausal flushing: double-blind trial of a non-hormonal medication. Br Med J 1974;1: 409–12
   PubMed Web of Science ®Google Scholar
• Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006;295:2057–71
   PubMed Web of Science ®Google Scholar
• Gallicchio L. Hot flushes and blood pressure in midlife women. Maturitas 2010;65:69–74
   PubMed Web of Science ®Google Scholar
• Moe KE. Hot flushes and sleep in women. Sleep Med Rev 2004;8:487–97
   PubMed Web of Science ®Google Scholar
• Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes 2005;3:4–7
   PubMedGoogle Scholar
• Crawford SL, Casey VA, Avis NE, McKinlay SM. A longitudinal study of weight and the menopause transition: results from Massachusetts Women's Health Study. Menopause 2000;7:96–104
   PubMed Web of Science ®Google Scholar
• Ng AV, Callister R, Johnson DG, Seals DR. Age and gender influence muscle sympathetic nerve activity at rest in healthy humans. Hypertension 1993;21:498–503
   PubMed Web of Science ®Google Scholar
• Mercuro G, Longu G, Zoncu S, Cherchi A. Impaired forearm blood flow and vasodilator reserve in healthy postmenopausal women. Am Heart J 1999;137:692–7
   PubMed Web of Science ®Google Scholar
• Kaaja R, Manhem K, Tuomilehto J. Treatment of postmenopausal hypertension with moxonidine, a selective imidazoline receptor agonist. IJCP 2004;(Suppl 139):S26–32
   Google Scholar
• Haenni L, Lithell H. Mxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens 1999;3(Suppl): S29–35
   Google Scholar
• Jacob S, Klimm HJ, Rett K, Heslbeg K, Haring HU, Gödicke J. Effects of moxonidine vs. metoprolol on blood pressure and metabolic control in hypertensive subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2004;112:315–22
   PubMed Web of Science ®Google Scholar
• Burt VL, Whelton P, Rocella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 1995;25:305–13
   PubMed Web of Science ®Google Scholar
• Wassertheil-Smoller S, Anderson G, Psaty BM, et al. Hypertension and its treatment in postmenopausal women. Baseline data from the Women's Health Initiative. Hypertension 2000;36: 780–9.
   PubMed Web of Science ®Google Scholar
• Hansson L, Zanchetti A, Carruthers SG, et al.; the HOT Study Group. Effects of intensive blood-pressure lowering and low- dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998;351:1755–62
   PubMed Web of Science ®Google Scholar